Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q1 FY23 results · Apr–Jun 2022
Gufic Biosciences reported revenue from operations of ₹165.28 crore (down 34.1% from Q1 FY22) and net profit of ₹21.05 crore (down 32.5% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a standalone basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 165.28 | 250.76 | −34.1% | 162.19 | +1.9% |
| Other income | 0.37 | 1.23 | −69.5% | 0.04 | +820.6% |
| Total income | 165.65 | 251.99 | −34.3% | 162.23 | +2.1% |
| Profit before tax | 28.28 | 41.54 | −31.9% | 26.18 | +8.0% |
| Net profit for the period | 21.05 | 31.21 | −32.5% | 20.26 | +3.9% |
| EPS, basic (₹) | 2.17 | 3.22 | −32.6% | 2.09 | +3.8% |
| Net margin (%) | 12.7 | 12.4 | 12.5 |
Standalone
- Filed with BSE
- 06 Sep 2022, 12:53 IST
- Board meeting
- 11 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE